key: cord-0983254-hz5g8o8q
authors: Kamrath, Clemens; Rosenbauer, Joachim; Eckert, Alexander J.; Ohlenschläger, Ute; Sydlik, Carmen; Nellen‐Hellmuth, Nicole; Holl, Reinhard W.
title: Glycated hemoglobin at diagnosis of type 1 diabetes and at follow‐up in children and adolescents during the COVID‐19 pandemic in Germany
date: 2022-04-10
journal: Pediatr Diabetes
DOI: 10.1111/pedi.13338
sha: 49c2e681b3a11c8d3b771d0a80cbe6e08c5463b2
doc_id: 983254
cord_uid: hz5g8o8q

BACKGROUND: This study investigated the diagnostic delay and the subsequent quality of care during the Covid‐19 pandemic among children with new‐onset type 1 diabetes. METHODS: We compared the HbA(1c) levels of 3111 children at diagnosis of type 1 diabetes and of 2825 children at a median follow‐up of 4.7 months (interquartile range, 4.1–5.4) together with their daily insulin requirement during the Covid‐19 pandemic with the two previous years via multivariable linear regression, using data from the German Diabetes Registry DPV. RESULTS: During the Covid‐19 pandemic, HbA(1c) levels were higher at diagnosis of type 1 diabetes (mean estimated difference, 0.33% [95% confidence interval, 0.23–0.43], p < 0.001), but not at follow‐up (mean estimated difference, 0.02% [−0.02–0.07]). Children with diabetes onset during the Covid‐19 pandemic had a significantly higher daily insulin requirement after initiation of therapy (mean estimated difference, 0.08 U/kg [0.06–0.10], p < 0.001). Both the increase in HbA(1c) and daily insulin requirement were evident only after the first wave of the pandemic. CONCLUSIONS: This increase in HbA(1c) at diagnosis of type 1 diabetes during the Covid‐19 pandemic may indicate a delay in seeking medical care due to the pandemic. However, this did not affect short‐term glycemic control. The increased insulin requirement at follow‐up could suggest a more rapid autoimmune progression during the pandemic.

The aim of this study was to quantify the diagnostic delay and its impact on subsequent quality of care during the Covid-19 pandemic in Germany by comparing the levels of glycated hemoglobin (HbA 1c ) at diagnosis of type 1 diabetes and after initiation of therapy during the Covid-19 pandemic with those of the two previous years.

This study compared HbA 1c levels of children and adolescents from the German Diabetes Prospective Follow-up Registry (DPV) at diagnosis of type 1 diabetes in the year 2020, at follow-up 2-8 months later, and daily insulin requirement (units per kilogram body weight), with data from 2018 and 2019 via multivariable linear regression, adjusted for age group (<6, 6-<12, and 12-<18 years), sex, and immigrant background (patient or at least one parent born outside Germany). Adjusted differences with the corresponding 95% confidence interval (CI) were presented for the whole year, as well as for four different periods related to the Covid-19 pandemic: the prepandemic period (January and February 2020), the first wave of the pandemic from March to May 2020, the period from June to September 2020 with a relatively low rate of new infections, and the 2nd wave starting October 2020. 7

The DPV registry has a nationwide coverage of more than 90% of pediatric patients with type 1 diabetes in Germany and comprises A two-sided p-value <0.05 was considered statistically significant.

All analyses were performed with SAS version 9.4 (SAS Institute Inc., NC, USA).

We obtained HbA 1c values at diabetes diagnosis from 3111 children and adolescents (55.5% males; median age 9. Table 2A ). The difference in adjusted HbA 1c at diagnosis between 2020 and 2019/2018 was significant in all age groups and both sexes (Table 2A) . Analysis by periods showed that the difference in HbA 1c was significant after the first wave of the pandemic (Table 2B ). In contrast, the HbA 1c during follow-up no longer differed (mean estimated difference, 0.02% [95% CI, À0.02-0.07]; Table 2C ), not even in the patients who developed diabetes after the first Covid-19 wave (Table 2D) . However, children with diabetes onset during the Covid-19 pandemic had a significantly higher daily insulin dose after initiation of therapy (mean estimated difference, 0.08 U/kg [95% CI, 0.06-0.10], p < 0.001; Table 2E ). Compared to the 2 years before the pandemic, the increased insulin requirements affected those children who developed type 1 diabetes after the first wave of the Covid-19 pandemic. (Table 2F ).

This study found an increase in HbA 1c at diagnosis of type 1 diabetes after the first wave of the Covid-19 pandemic in Germany, which may indicate a delay in seeking medical care due to the pandemic. This delay is probably the main reason for the increased frequency of diabetic ketoacidosis in children with new-onset type 1 diabetes during the pandemic. [3] [4] [5] [6] However, this did not affect short-term treatment response, as the identical HbA 1c at follow-up excludes major limitations in the care of chronically ill children. This also corresponds to reports on the metabolic control of children with type 1 diabetes during the Covid-19 lockdown, which did not noticeably worsen. 9, 10 It has been demonstrated that the incidence of type 1 diabetes in children increased only a few months after the Covid-19 waves. 11, 12 With this background, it is important to note that we found an increased insulin requirement in children with onset of type 1 diabetes after the first wave of the Covid-19 pandemic. This may indicate more rapid autoimmune destruction of beta cells during the pandemic. Importantly, the difference in the required daily weight-adjusted insulin amount was not due to differences in BMI and consequent differences in insulin sensitivity. T A B L E 2 Adjusted mean HbA 1c at diagnosis and at follow-up, and adjusted daily insulin dose at follow-up of children and adolescents with new-onset type 1 diabetes in 2020 versus 2018/2019

In 2020-adjusted mean (95% CI) 

Reductions in hospital admissions and delays in acute stroke care during the pandemic of COVID-19

Delays in presentation in patients with acute myocardial infarction during the COVID-19 pandemic

Ketoacidosis in children and adolescents with newly diagnosed type 1 diabetes during the COVID-19 pandemic in Germany

Incidence of COVID-19 and risk of diabetic ketoacidosis in new-onset type 1 diabetes. Pediatrics

Increased paediatric presentations of severe diabetic ketoacidosis in an Australian tertiary Centre during the COVID-19 pandemic

Diabetic ketoacidosis at type 1 diabetes diagnosis in children during the COVID-19 pandemic

Body mass index percentiles for children and adolescents in Germany based on a nationally representative sample

Metabolic control during the SARS-CoV-2 lockdown in a large German cohort of pediatric patients with type 1 diabetes: results from the DPV initiative

Comparison of the effects of lockdown due to COVID-19 on glucose patterns among children, adolescents, and adults with type 1 diabetes: CGM study

New-onset type 1 diabetes in Finnish children during the COVID-19 pandemic

Incidence of type 1 diabetes in children and adolescents during the Covid-19 pandemic in Germany: results from the DPV registry. Diabetes Care. 2022; dc210969

Glycated hemoglobin at diagnosis of type 1 diabetes and at follow-up in children and adolescents during the COVID-19 pandemic in Germany

The authors declare no potential conflict of interest.

Clemens Kamrath conceptualized the study, interpreted the analyses, wrote the initial manuscript, and revised the manuscript. Joachim Rosenbauer analyzed the data, designed and supervised the statistical analysis, and critically reviewed and revised the manuscript. Alexander J. Eckert analyzed the data and designed the analyses, contributed to the interpretation of results, and reviewed and revised the manuscript. Reinhard W. Holl conceptualized the study, coordinated and supervised data collection, acquired funding for the study, and critically reviewed the manuscript for important intellectual content. UteOhlenschläger, Carmen Sydlik, and Nicole Nellen-Hellmuth collected data, contributed intellectually to the research topics of the DPV initiative, and critically reviewed the scientific content of the manuscript.All authors approved the final manuscript as submitted and agreed to be accountable for all aspects of the work.

The ethics committee of Ulm University approved the analysis of anonymized data from the DPV registry.

The peer review history for this article is available at https://publons. com/publon/10.1111/pedi.13338.

Access to the data is possible by remote data processing upon request and approval from the DPV board.

https://orcid.org/0000-0002-8241-4105Joachim Rosenbauer https://orcid.org/0000-0002-6086-2230